To assess the one-month ocular effects of nightly application of experimental BHVI2 and 0.02% atropine eye drops either alone or in combination, in children aged between 6 to 13 years old with myopia and randomized to use of experimental BHVI2 eye drops, 0.02% atropine eye drops, experimental BHVI2 plus 0.02% atropine eye drops.
Atropine was proven to be effective in controlling myopia. 7-methylxanthine was considered to play a role in slowing myopia. The experimental BHVI2 eye drops were proven to be safe for in-eye use in the trial that was conducted in Sydney, Australia. The investigators wish to evaluate the effects of experimental BHVI2 and 0.02% atropine eye drops either alone or in combination mainly on the pupillary and accommodative responses in children aged between 6 to 13 years old over a one-month period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Enrollment
52
Experimental BHVI2 eye drops
Atropine eye drops
Combination eye drops with experimental BHVI2 plus 0.02% atropine
Department of Ophthalmology - An Sinh Hospital
Ho Chi Minh City, Vietnam
Change in pupillary diameter
Measure and compare the photopic and mesopic pupil size (milimeters) before and after instillation of eye drops
Time frame: At baseline, at two-week and one-month visits
Change in accommodative amplitude
Measure and compare the accommodative amplitude (diopters) before and after instillation of eye drops
Time frame: At baseline, at two-week and one-month visits
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.